18 November 2021, Shanghai - Mindfront Health, the global mental service brand of Luye Medical Group opened a new outpatient center in Crystal Galleria, Jing’an CBD, Shanghai, China. Supported b...
November 15, 2021, Shanghai, China – Luye Pharma Group today announced that it has submitted the Investigational New Drug (IND) application for its innovative microspheres injection LY03009 in t...
October 13, 2021, Shanghai -- Luye Pharma Group announced that the marketing authorization application for the Denosumab Injection (LY06006 / BA6101), developed by Boan Biotech, a subsidiary of the Gr...
Luye Pharma Group today announced that BA1105, a novel antibody developed by its subsidiary Boan Biotech, has been approved by the Center for Drug Evaluation (CDE) of China's National Medical Prod...
Luye Pharma Group today announced that LY03015, a next-generation Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, has been approved by the Centre for Drug Evaluation (CDE) of China’s Nation...
Research results from a study into Luye Pharma’s in-house developed LY03015, a next-generation vesicular monoamine transporter 2 (VMAT2) inhibitor, were recently published in the European Journa...
September 27, 2021, Shanghai, China – Luye Pharma Group today announced that Dulaglutide Injection (BA5101) developed in-house by Boan Biotech, a subsidiary of the Group, has obtained approval f...
September 26, 2021, Boston, USA - Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific anti...
September 23,2021. Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD) has been granted by the UK’...
Luye Pharma Group announced today that a Phase III clinical trial of its innovative formulation for the treatment of prostate cancer, Goserelin Acetate Extended-release Microspheres for Injection (LY0...